Analyses / Public Summary / 119 · HRES 803 Public Summary

119-HRES-803 Journalist Public Summary

119 · HRES 803 Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

health_and_safety Health

A House resolution urges the FDA to re-check the safety of medication abortion drugs and publish a full review; it’s a statement of the House’s position, not a change to law or access.

Analyzed as
Journalist
Published
11 Oct 2025
Updated
11 Oct 2025
Tags
public-summary · U.S. House · FDA
Unvetted
01 · Section

Headline Summary

A House resolution asks the FDA to reevaluate the safety of medication abortion drugs and publicly release a full safety review; it signals the House’s view and does not change the law by itself.

02 · Section

What It Does

H. Res. 803 urges FDA leadership to take another look at the safety of medication abortion (sometimes called “chemical abortion”) and to publish a comprehensive review that covers real‑world outcomes and complications. The resolution’s sponsors argue FDA access rules were loosened in recent years, a new generic version of mifepristone was approved, and that independent studies suggest safety risks are being underreported. The measure expresses the House’s position; it does not direct the FDA or change federal policy on its own.

03 · Section

Who’s For It

  • Introduced by Rep. John Rose (R‑TN) with seven Republican co‑sponsors: Reps. Diana Harshbarger (R‑TN), Earl “Buddy” Carter (R‑GA), Doug LaMalfa (R‑CA), Sheri Biggs (R‑SC), Barry Moore (R‑AL), Harriet Hageman (R‑WY), and Glenn Grothman (R‑WI).
  • Supporters say the FDA relaxed safeguards (like in‑person requirements), that complications are underreported, and that a transparent, up‑to‑date safety review is needed to protect patients.
04 · Section

Who’s Against It

  • Democratic lawmakers and abortion‑rights advocates typically oppose measures like this, arguing medication abortion has long been FDA‑approved, that it is safe and effective when used as directed, and that such resolutions can stigmatize care or interfere with patient‑provider decisions.
  • Public‑health and medical groups that support current FDA standards often argue safety monitoring already exists and that changing dispensing rules could reduce access, especially in rural areas.
05 · Section

What’s Next

The resolution was introduced on October 10, 2025, and sent to the House Committee on Energy and Commerce. If it advances and the House adopts it, it becomes an official statement of the House—but it does not go to the Senate or the President and does not change federal law or FDA policy by itself.

Discussion